Home207940 • KRX
add
Samsung Biologics Co Ltd
Nakaraang pagsara
₩1,585,000.00
Sakop ng araw
₩1,551,000.00 - ₩1,631,000.00
Sakop ng taon
₩982,000.00 - ₩1,987,000.00
Market cap
71.94T KRW
Average na Volume
50.08K
P/E ratio
41.95
Dividend yield
-
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.45T | 52.94% |
Gastos sa pagpapatakbo | — | — |
Net na kita | — | — |
Net profit margin | — | — |
Kita sa bawat share | 8.72K | 25.60% |
EBITDA | — | — |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.46T | 12.13% |
Kabuuang asset | 11.06T | -36.20% |
Kabuuang sagutin | 3.61T | -43.88% |
Kabuuang equity | 7.45T | — |
Natitirang share | 54.52M | — |
Presyo para makapag-book | 11.60 | — |
Return on assets | — | — |
Return on capital | — | — |
Cash Flow
Net change in cash
| (KRW) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | — | — |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Itinatag
2011
Website
Mga Empleyado
5,195
